HR8032 ensures equitable Medicare payment for cancer treatments, directly benefiting pharmaceutical companies and biotech firms focused on oncology. This bill stabilizes revenue streams for cancer drug manufacturers within the outpatient setting.
Impact: 6/10HR8032Congressional Bill